@article {Vitall{\'e}2022.01.07.22268806, author = {Joana Vitall{\'e} and Alberto P{\'e}rez-G{\'o}mez and Francisco Jos{\'e} Ostos and Carmen Gasca-Capote and Mar{\'\i}a Reyes Jim{\'e}nez-Le{\'o}n and Sara Bachiller and Inmaculada Rivas-Jerem{\'\i}as and Maria del Mar Silva-S{\'a}nchez and Anabel Ruiz-Mateos and Luis Fernando L{\'o}pez-Cortes and Mohammed Rafii-El-Idrissi Benhnia and Ezequiel Ruiz-Mateos}, title = {Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people}, elocation-id = {2022.01.07.22268806}, year = {2022}, doi = {10.1101/2022.01.07.22268806}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The immune factors associated with impaired SARS-CoV-2 vaccine response in the elderly are mostly unknown. We studied old and young people vaccinated with SARS-CoV-2 BNT162b2 mRNA before and after the first and second dose. Aging was associated with a lower anti-RBD IgG levels and a decreased magnitude and polyfunctionality of SARS-CoV-2 specific T cell response. The dramatic decrease in thymic function in the elderly, which fueled alteration in T cell homeostasis, and lower CD161+ T cell levels were associated with decreased T cell response two months after vaccination. Additionally, a deficient dendritic cell (DC) homing, activation and Toll like receptor (TLR)-mediated function, along with a proinflammatory functional profile in monocytes, were observed in the elderly, which was also related to lower specific T cell response after vaccination. These findings might be relevant for the improvement of the current vaccination strategies and for the development of new vaccine prototypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades, Junta de Andalucia (CV20-85418 and P20_00906, DOC-01659 and DOC-00963); Consejeria de Salud, Junta de Andalucia (RH-0037-2020), Instituto de Salud Carlos III (CP19/00159, FI17/00186, FI19/00083, PI19/01172, CM20/00243) Fondos FEDER, and National Spanish Research Council (CSIC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants gave written consent and the study was approved by the Ethics Committee of the Virgen del Rocio University Hospital (protocol code "COVIMARATON_2020"; internal code 0156-N-21).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/01/08/2022.01.07.22268806}, eprint = {https://www.medrxiv.org/content/early/2022/01/08/2022.01.07.22268806.full.pdf}, journal = {medRxiv} }